ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

about

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.

P2860

Q33766513-B4CFC248-84C7-407D-A2E0-3327617D9E44 Q48225891-84D0B392-C0C8-478D-BE18-09218DB6E3D6

P2860

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

Item

http://www.wikidata.org/entity/Q39106167

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@en

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@nl

type

Item

label

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@en

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@nl

prefLabel

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@en

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@nl

P1476

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

@en

P2093

Amy Bryson

http://www.w3.org/2001/XMLSchema#string

Katherine Reeder-Hayes

http://www.w3.org/2001/XMLSchema#string

Michaela A Dinan

http://www.w3.org/2001/XMLSchema#string

Morris Weinberger

http://www.w3.org/2001/XMLSchema#string

Stephanie B Wheeler

http://www.w3.org/2001/XMLSchema#string

P2860

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Barriers to the use of personalized medicine in breast cancer.

The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

Improving communication of breast cancer recurrence risk.

P304

355-361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S026646231600060X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stacie B. Dusetzina

Megan C Roberts

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27958190

http://www.w3.org/2001/XMLSchema#string

P932

6526532

http://www.w3.org/2001/XMLSchema#string

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

about

P2860

P2860

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932